Patients using antibacterial drugs including Megamox DT are at an increased risk. These patients may suffer from diarrhea
associated with Clostridium difficile bacteria that can lead to severe inflammation of the colon. If this happens, stop using this medicine and take antibiotics
, protein supplements or maintain the balance
of body fluid and electrolyte. If necessary, surgical evaluation should be done.
Development of Drug Resistant Bacteria
Megamox DT is not likely to provide benefit unless the patient uses it to treat a bacterial infection. Otherwise, the risk of developing drug-resistant bacteria is increased by the use of Megamox DT.
Patients with viral infection (also called mononucleosis
) caused by Epstein-Barr virus are at increased risk when using this medicine. These patients may suffer from skin rash. It is advised that Megamox DT should not be used in these patients.
Birth Defect Called Phenylketonuria
Patients with increased phenylalanine levels in the body are at an increased risk when using chewable tablets of Megamox DT. The chewable tablets should not be used in these patients if it contains phenylalanine. The oral suspension of Megamox DT can be used in these patients because it does not contain phenylalanine.
History of Brain and Spinal Cord Disorders
Patients using Megamox DT in high doses and have a history of seizures
, or brain and spinal cord disorders are at an increased risk. These patients may suffer from seizures.
Patients with kidney dysfunction are at an increased risk when using this medicine. In such patients, the dose should be adjusted according to the condition.
Patients using Megamox DT are at an increased risk of developing serious skin reactions. If this happens, stop using this medicine.
Patients with a bacterial infection caused by a tick bite (Lyme disease) are at an increased risk when using this medicine. These patients may suffer from allergic reactions called Jarisch-Herxheimer reaction.
Patients at prolonged therapy with Megamox DT are at an increased risk. These patients may develop changes in blood count and increase in liver enzymes. In such patients, monitoring of blood cells production, kidney and liver function is required.
Patients using blood thinners are at an increased risk when using this medicine. In these patients, blood clotting time is increased. The dose adjustment of blood thinners is required.
Patients with reduced urine output and bladder catheters are at an increased risk when using this medicine. These patients may suffer from cloudy urine. It is advised to maintain urinary output and adequate fluid intake to reduce the chances of cloudy urine. In patients with bladder catheters, a regular checkup is recommended.